IXHL (Incannex Healthcare) Momentum Rank : 0 (As of Dec. 13, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Incannex Healthcare Momentum Rank?

Incannex Healthcare has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Incannex Healthcare Momentum Rank Related Terms

Thank you for viewing the detailed overview of Incannex Healthcare's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Incannex Healthcare Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Inc (NAS:IXHL) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000

Website

https://www.incannex.com.au

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.